gsk3923868
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 12, 2020 (NCT04585009)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- PI4-kinase beta subunitINHIBITOR
PI4KB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06597500 | Phase 1 | Sep 30, 2024 | GlaxoSmithKline |
| NCT06577597 | Phase 1 | Sep 2, 2024 | GlaxoSmithKline |
| NCT05677347 | Phase 1 | Jan 23, 2023 | GlaxoSmithKline |
| NCT05398198 | Phase 1 | Jun 9, 2022 | GlaxoSmithKline |
| NCT04585009 | Phase 1 | Oct 12, 2020 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 1 | 2020 |
1 organizations
Page 1 / 1